Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ossama Labib

Internal Medicine Fall River, MA Medical Doctor

NPI 1225033673 CMS profile 55535

1200 Robeson St, Fall River, MA 02720

Open in the dashboard

General payments

$11,511

624 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ossama Labib of Fall River, MA is reported in the CMS Open Payments database as having received $11,511 across 624 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,143 51
2024 General $1,641 72
2023 General $1,942 90
2022 General $1,875 99
2021 General $2,319 139
2020 General $1,406 86
2019 General $1,185 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ossama Labib
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ossama Labib were reported at $1,143. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ossama Labib Internal Medicine median Middle half National median
2019 $1,185 $159 $48–$570 $163
2020 $1,406 $119 $33–$402 $114
2021 $2,319 $135 $37–$521 $132
2022 $1,875 $141 $42–$496 $149
2023 $1,942 $149 $45–$519 $160
2024 $1,641 $154 $47–$537 $164
2025 $1,143 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,036 91 payments
  2. GlaxoSmithKline, LLC. $1,352 69 payments
  3. Pfizer Inc. $1,006 75 payments
  4. AbbVie, Inc. $998 59 payments
  5. Merck Sharp & Dohme Corporation $555 28 payments
  6. Teva Pharmaceuticals USA, Inc. $541 26 payments
  7. Janssen Pharmaceuticals, Inc $434 31 payments
  8. Novo Nordisk Inc $421 26 payments
  9. Nestle HealthCare Nutrition Inc. $393 19 payments
  10. Amgen Inc. $384 24 payments
  11. Other $3,392 176 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,401 622 payments
  2. Education $111 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,141 59 payments
  2. FARXIGA $743 30 payments
  3. BREZTRI $731 28 payments
  4. ELIQUIS $633 41 payments
  5. CREON $544 32 payments
  6. ZENPEP $469 22 payments
  7. XARELTO $434 31 payments
  8. AREXVY $429 18 payments
  9. BELSOMRA $421 21 payments
  10. VERQUVO $417 20 payments
  11. Other $9,806 580 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 249 drugs

Part D claims

28,330

Median for Internal Medicine: 777

Drug cost

$2,159,766

Median for Internal Medicine: $73,373

Branded share of claims

21.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 625 $310,102
Trulicity Dulaglutide Brand 209 $222,654
Farxiga Dapagliflozin Propanediol Brand 392 $213,169
Ozempic Semaglutide Brand 123 $142,155
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 211 $137,324
Xarelto Rivaroxaban Brand 220 $96,341
Linzess Linaclotide Brand 100 $73,889
Rybelsus Semaglutide Brand 42 $58,737
Jardiance Empagliflozin Brand 82 $58,502
Mounjaro Tirzepatide Brand 34 $49,729

The 10 drugs with the highest cost, of 249 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$254,824

Medicare's payments for the services billed

Medicare patients

466

Average age 73

Services billed

6,537

235 women, 231 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Depression 38%
Arthritis 38%
COPD 37%
Ischemic heart disease 30%
Alzheimer's or dementia 30%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $227
$227 26 —
UBRELVY
  • AbbVie, Inc. $211
$211 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $146
$146 211 —
AREXVY
  • GlaxoSmithKline, LLC. $123
$123 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

624 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record